Should I buy or sell Jasper Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JSPR shares. View JSPR analyst ratings or view top-rated stocks .

What is Jasper Therapeutics' stock price target for 2024?

5 Wall Street research analysts have issued 1 year price targets for Jasper Therapeutics' stock. Their JSPR share price targets range from $4.00 to $7.00. On average, they predict the company's stock price to reach $5.96 in the next twelve months. This suggests a possible upside of 1,069.1% from the stock's current price. View analysts price targets for JSPR or view top-rated stocks among Wall Street analysts .

How have JSPR shares performed in 2023?

Jasper Therapeutics' stock was trading at $0.4829 on January 1st, 2023. Since then, JSPR stock has increased by 5.6% and is now trading at $0.51. View the best growth stocks for 2023 here .

When is Jasper Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024. View our JSPR earnings forecast .

How were Jasper Therapeutics' earnings last quarter?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.01.

Who are Jasper Therapeutics' major shareholders?

Jasper Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Mariner LLC (0.59%), Cowen AND Company LLC (0.18%), Forefront Analytics LLC (0.10%), Summit Trail Advisors LLC (0.06%) and Walleye Capital LLC (0.00%). Insiders that own company stock include Anna Louise French, Carlyle Group Inc, Holding Ltd Roche, Jeetinder Singh Mahal, Thomas G Wiggans and William Lis. View institutional ownership trends .

How do I buy shares of Jasper Therapeutics?

Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Jasper Therapeutics Stock Price, News & Analysis (NASDAQ:JSPR)

$0.51

-0.01 (-1.92%)

(As of 12/8/2023 ET)

Compare

Today's Range: $0.48
▼
$0.53
50-Day Range: $0.51
▼
$0.93
52-Week Range: $0.39
▼
$3.80

Volume: 2.01 million shs
Average Volume: 272,043 shs
Market Capitalization: $56.90 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.96

Jasper Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,069.1% Upside
$5.96 Price Target
Short Interest: Bearish
2.30% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$12,300 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.62) to ($0.67) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

349th out of 942 stocks

Biological Products, Except Diagnostic Industry

57th out of 161 stocks

3.5

Analyst's Opinion

Consensus Rating
Jasper Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.96, Jasper Therapeutics has a forecasted upside of 1,069.1% from its current price of $0.51.
Amount of Analyst Coverage
Jasper Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.30% of the float of Jasper Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Jasper Therapeutics has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in Jasper Therapeutics has recently increased by 1.09%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Jasper Therapeutics does not currently pay a dividend.
Dividend Growth
Jasper Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for JSPR.

0.6

News and Social Media Coverage

Search Interest
Only 1 people have searched for JSPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
2 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Jasper Therapeutics insiders have bought 81.68% more of their company's stock than they have sold. Specifically, they have bought $12,300.00 in company stock and sold $6,770.00 in company stock.
Percentage Held by Insiders
Only 3.90% of the stock of Jasper Therapeutics is held by insiders.
Percentage Held by Institutions
79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Jasper Therapeutics are expected to decrease in the coming year, from ($0.62) to ($0.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Jasper Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Jasper Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Jasper Therapeutics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Jasper Therapeutics Stock (NASDAQ:JSPR)

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

JSPR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

JSPR Stock News Headlines

November 30, 2023 | finanznachrichten.de

Jasper Therapeutics: Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

November 30, 2023 | finance.yahoo.com

Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 9, 2023 | msn.com

Jasper Therapeutics GAAP EPS of -$0.16 in-line

November 9, 2023 | benzinga.com

Jasper Therapeutics: Q3 Earnings Insights

November 9, 2023 | finance.yahoo.com

Jasper Therapeutics Inc (JSPR) Reports Q3 2023 Financial Results and Business Progress

November 9, 2023 | finance.yahoo.com

Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 8, 2023 | finance.yahoo.com

Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

November 2, 2023 | finance.yahoo.com

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

November 1, 2023 | finance.yahoo.com

Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

October 23, 2023 | thestreet.com

Jasper Therapeutics Inc.

October 10, 2023 | finance.yahoo.com

Jasper Therapeutics, Inc.'s (NASDAQ:JSPR) high institutional ownership speaks for itself as stock continues to impress, up 25% over last week

October 10, 2023 | msn.com

Jasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria Study

October 9, 2023 | finance.yahoo.com

Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria

October 9, 2023 | finance.yahoo.com

Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023

September 25, 2023 | markets.businessinsider.com

Jasper Therapeutics Appoints Herb Cross As New CFO

September 21, 2023 | finance.yahoo.com

Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium

September 15, 2023 | finance.yahoo.com

Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference

August 12, 2023 | finanznachrichten.de

Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

August 4, 2023 | finance.yahoo.com

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 2, 2023 | finance.yahoo.com

Jasper Therapeutics Strengthens Management Team with Key Appointments

July 5, 2023 | fool.com

Jasper Therapeutics (NASDAQ: JSPR)

June 22, 2023 | finance.yahoo.com

Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome

June 21, 2023 | benzinga.com

Jasper Therapeutics Director Awarded $128K Worth of Stock Options

June 20, 2023 | finance.yahoo.com

Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

June 20, 2023 | finance.yahoo.com

Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

See More Headlines

Receive JSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/13/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:JSPR
CUSIP: N/A
CIK: 1788028
Web: jaspertherapeutics.com
Phone: 650-549-1400
Fax: N/A
Employees: 35
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.96
High Stock Price Target: $7.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +1,069.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,690,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -66.86%
Return on Assets: -57.95%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.84
Quick Ratio: 8.84

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.95 per share
Price / Book: 0.54

Miscellaneous

Outstanding Shares: 111,575,000
Free Float: 107,224,000
Market Cap: $56.90 million
Optionable: Not Optionable
Beta: 1.91

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Ronald A. Martell (Age 61)
President, CEO & Director
Comp: $892.45k
Dr. Judith Anne Shizuru M.D. (Age 67)
Ph.D., Co-Founder, Chair of Scientific Advisory Board & Director
Comp: $291.25k
Mr. Jeetinder Singh Mahal M.B.A. (Age 51)
Chief Operating Officer
Comp: $579.46k
Mr. Herbert C. Cross (Age 51)
CFO & Corporate Secretary
Dr. Luca Di Noto Ph.D.
Senior Vice President of Technical Operations
Mr. David Ku M.D.
Vice President of Corporate Development, Portfolio Strategy & Management
Mr. Matthew Ford
Vice President of Human Resources
Dr. Wendy Pang M.D.
Ph.D., Senior Vice President of Research & Translational Medicine
Dr. Edwin Jonathan Tucker M.D. (Age 51)
Chief Medical Officer
Ms. Patricia Carlos
Senior Vice President of Regulatory Affairs & Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JSPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Jasper Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JSPR shares.
View JSPR analyst ratings or view top-rated stocks.
What is Jasper Therapeutics' stock price target for 2024?: 5 Wall Street research analysts have issued 1 year price targets for Jasper Therapeutics' stock. Their JSPR share price targets range from $4.00 to $7.00. On average, they predict the company's stock price to reach $5.96 in the next twelve months. This suggests a possible upside of 1,069.1% from the stock's current price.
View analysts price targets for JSPR or view top-rated stocks among Wall Street analysts.
How have JSPR shares performed in 2023?: Jasper Therapeutics' stock was trading at $0.4829 on January 1st, 2023. Since then, JSPR stock has increased by 5.6% and is now trading at $0.51.
View the best growth stocks for 2023 here.
When is Jasper Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our JSPR earnings forecast.

How were Jasper Therapeutics' earnings last quarter?: Jasper Therapeutics, Inc. (NASDAQ:JSPR) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.01.
Who are Jasper Therapeutics' major shareholders?: Jasper Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Mariner LLC (0.59%), Cowen AND Company LLC (0.18%), Forefront Analytics LLC (0.10%), Summit Trail Advisors LLC (0.06%) and Walleye Capital LLC (0.00%). Insiders that own company stock include Anna Louise French, Carlyle Group Inc, Holding Ltd Roche, Jeetinder Singh Mahal, Thomas G Wiggans and William Lis.
View institutional ownership trends.
How do I buy shares of Jasper Therapeutics?: Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:JSPR) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial